TABLE 1.

Binding of CTL vaccine epitopes to solubilized HLA-A and HLA-B proteins

Epitope	Sequence	Previous documentation of immunogenicitya	Conservation (%)	HLA-A2 supertype binding capacity (IC50, in nM)b								HLA-A2 supertype binding capacity (IC50, in nM)b
				A*0201	A*0202	A*0203	A*0206	A*6802	A*0301	A*1101	A*3101	A*3301	A*6801	B*0702	B*3501	B*5101	B*5301	B*5401	A*0101	A*2902	A*3002	A*2301	A*2402
core 18	FLPSDFFPSV	3, 5, 40	45	3.5	2.2	4.4	3.1	7.7
env 183	FLLTRILTI	5, 40	80	10.4	106.7	1.3	18.6	8000
env 335	WLSLLVPFV	5, 35, 40	100	4.4	252.9	1.8	11.2	293.5
pol 455	GLSRYVARL	5, 40	55	46.9	390.9	18
pol 538	YMDDVVLGV	*	90	5.4	90.6	11.5	90.6	421.6
pol 562	FLLSLGIHL	5, 40	95	7.8	106.3	988.7	50.6	2330.9
core 141	STLPETTVVRR	5, 32	95						735	4.5	190	187.2	27.1
pol 149	HTLWKAGILYK	5	100						15.4	15.6	536.2	403.4	48.2
pol 388	LVVDFSQFSR	5	100						6875	16.7	706	142.2	16.9
pol 47	NVSIPWTHK	5	100						174.7	214			283
pol 531	SAICSVVRR	5	95						2190	29.4	1355.7	461.4	22.9
pol 665	QAFTFSPTYKc		95						249.1	8.4	18000	5273.6	7.1
core 19	LPSDFFPSV	5	45											3026.8	289.2	11.6		6.2
env 313	IPIPSSWAF	5	100											42.3	2.6	2.6		3368.5
pol 354	TPARVTGGVF	5	90											13.2	71.6		139.8
pol 429	HPAAMPHLL	*	100											56.6	297.7	543.5	160.4	923.3
pol 530	FPHCLAFSYM	*	95											58.5	57.6	68.9	127.5	214
pol 640	YPALMPLYACI	New	95											1393.4		119.2	390.4	111
env 359	WMMWYWGPSLYc	New	85																16.3	133.4	46.4
core 419	DLLDTASALYc	New	75																2.3	74.1	37
core 137	LTFGRETVLEYc		75																16.8	27.8	430.8
pol 166	ASFCGSPYc		100																51.4	86.9	4.3
pol 415	LSLDVSAAFYc		95																333.3	44.2	3.7
env 249	ILLLCLIFLLc		100																29.9	1769.9	504.6
env 236	RWMCLRRFIIc	New	95																			7.5	10.2
env 332	RFSWLSLLVPFc	New	100																			12.6	100.8
core 101	LWFHISCLTFc	New	85																			7.7	6.5
core 117	EYLVSFGVW	52	90																			16.5	4.9
pol 392	SWPKFAVPNLc		95																			1	2.4
pol 745	KYTSFPWLL	52	85																			1	2.3

^aAn asterisk indicates that immunogenicity was previously described for HLA transgenic mice [A02(18); B07 (2)]. New indicates that the immunogenicity of this epitope was demonstrated for the first time in this paper.

^bIC₅₀, 50% inhibitory concentration.

^cNovel epitopes.